ArticleFrontiers in nutrition2026
Ninjin'yoeito is associated with attenuation of postoperative decline in Prognostic Nutritional Index in patients with oral squamous cell carcinoma: a single-center, open-label, single-arm study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative nutritional deterioration and immunosuppression are clinically important in patients undergoing surgery for oral squamous cell carcinoma (OSCC). The Prognostic Nutritional Index (PNI), calculated from serum albumin and total lymphocyte count, is associated with the prognosis of OSCC. Ninjin'yoeito (NYT), a traditional Japanese Kampo medicine, has been reported to exert orexigenic and immunomodulatory effects. We evaluated whether perioperative NYT administration was associated with attenuation of postoperative PNI decline in patients with OSCC. Methods: This single-center, open-label, single-arm interventional study was conducted at Kagoshima University Hospital, approved by a Certified Review Board, and registered with the Japan Registry of Clinical Trials (jRCTs071230055). Patients with OSCC scheduled for curative surgery received NYT (7.5 g/day) from the preoperative period through postoperative week 8. The primary endpoint was the change in PNI from baseline to postoperative week 8, compared with a prespecified historical threshold (-4.95) using one-sample Results: Nineteen patients completed the study protocol and were included in the efficacy and safety analyses. The mean change in PNI at postoperative week 8 was -2.576 (95% CI, -4.743 to -0.410), which was significantly better than the historical threshold ( Conclusion: Perioperative NYT administration was associated with attenuation of postoperative PNI decline in patients undergoing OSCC surgery. NYT was well tolerated, supporting the feasibility of its perioperative use. Controlled trials are warranted to confirm clinical benefits and evaluate long-term outcomes of NYT use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.